Indivior PLC (INDV) Stock Rating Reaffirmed by Stifel Nicolaus
Indivior PLC (LON:INDV)‘s stock had its “buy” rating reiterated by equities researchers at Stifel Nicolaus in a research report issued on Friday. They presently have a GBX 400 ($5.17) target price on the specialty pharmaceutical company’s stock. Stifel Nicolaus’ price target suggests a potential upside of 35.36% from the company’s previous close.
Several other research analysts also recently issued reports on the stock. Numis Securities Ltd restated a “buy” rating and set a GBX 490 ($6.33) price objective on shares of Indivior PLC in a report on Tuesday, July 11th. Jefferies Group LLC restated a “buy” rating and set a GBX 490 ($6.33) price objective on shares of Indivior PLC in a report on Wednesday, June 7th. Citigroup Inc. restated a “neutral” rating and set a GBX 280 ($3.62) price objective on shares of Indivior PLC in a report on Tuesday, September 5th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a GBX 470 ($6.07) price objective on shares of Indivior PLC in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of GBX 395.50 ($5.11).
Shares of Indivior PLC (LON:INDV) traded up 1.56% during mid-day trading on Friday, hitting GBX 300.10. The stock had a trading volume of 1,844,107 shares. The stock has a 50-day moving average price of GBX 371.14 and a 200 day moving average price of GBX 336.83. Indivior PLC has a 52 week low of GBX 246.50 and a 52 week high of GBX 421.50. The stock’s market cap is GBX 2.16 billion.
ILLEGAL ACTIVITY NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/15/indivior-plc-indv-stock-rating-reaffirmed-by-stifel-nicolaus.html.
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.